Dr. Paul Goepfert is professor of medicine and microbiology, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, and the director of the Alabama Vaccine Research Clinic (AVRC), which is largely funded through a National Institutes of Health grant as part of the HIV Vaccine Trials Network (HVTN). He is board-certified in medicine and infectious diseases. He is currently studying immune responses to SARS-CoV-2 as well as working on SARS-CoV-2 clinical vaccine studies.
His research interests are focused on T cell immunology and vaccine design. He has published over 70 papers detailing HIV specific immune responses in HIV infected patients and vaccine recipients. Dr. Goepfert’s laboratory was one of the first to demonstrate the relative functional deficiencies of HIV specific CD8 T cells, describe the importance of targeting the Gag protein, and demonstrate that peptides, derived from antisense transcripts, are able to induce responses to HIV. He has performed this work via National Institutes of Health (NIH) funding sources for the last 12 years. Dr. Goepfert’s clinical research interest is centered on the testing of preventive HIV vaccines. His involvement in clinical HIV vaccine trials began in 1994 while he was an infectious disease fellow.
He has conducted not only preventive HIV vaccine trials but also vaccines designed to prevent diseases such as anthrax, HPV, HBV, HSV, and smallpox. He is an author of over 25 papers detailing the safety and immunogenicity of HIV vaccine products.